Ironwood Pharmaceuticals, Inc.
IRWD
$1.27
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -9.70% | -45.05% | -22.98% | -19.47% | -12.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.70% | -45.05% | -22.98% | -19.47% | -12.09% |
| Cost of Revenue | -23.08% | 6.26% | -32.43% | -9.02% | 53.65% |
| Gross Profit | -3.35% | -72.05% | -4.41% | -23.70% | -26.94% |
| SG&A Expenses | -54.56% | -35.49% | -28.48% | 11.65% | 17.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.36% | -18.49% | -31.69% | 1.24% | 31.13% |
| Operating Income | 66.66% | -192.07% | 1.13% | -47.23% | -51.73% |
| Income Before Tax | 100.37% | -831.59% | -20.97% | -45.61% | 101.75% |
| Income Tax Expenses | -27.93% | -87.79% | -32.29% | -23.68% | 48.88% |
| Earnings from Continuing Operations | 2,844.07% | -798.27% | 229.28% | -73.86% | 99.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2,844.07% | -798.27% | 307.54% | -76.20% | 99.92% |
| EBIT | 66.66% | -192.07% | 1.13% | -47.23% | -51.73% |
| EBITDA | 65.29% | -184.13% | 1.03% | -45.92% | -51.06% |
| EPS Basic | 2,801.85% | -779.55% | 301.43% | -76.81% | 99.92% |
| Normalized Basic EPS | 76.43% | -421.50% | -5.98% | -60.28% | -80.81% |
| EPS Diluted | 1,474.00% | -674.00% | 274.07% | -77.27% | 99.85% |
| Normalized Diluted EPS | 61.36% | -421.50% | -5.98% | -52.52% | -80.81% |
| Average Basic Shares Outstanding | 1.70% | 2.08% | 2.20% | 2.45% | 2.35% |
| Average Diluted Shares Outstanding | 11.21% | 2.08% | 2.20% | -14.26% | 2.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |